PepTrackevidence-graded reference
CJC-1295 / Ipamorelin
fig.1 — stylized molecular motif
GH secretagogue

CJC-1295 / Ipamorelin

mod-GRF(1-29) · NNC 26-0161

Most-searched peptide COMBINATION; the default GH-optimization stack in clinics and biohacking.

Evidence
Bhuman trials
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
GH secretagogue
Route
Subcutaneous
Demand rank
#7 most-searched
01Dosing & Protocol
Typical · reference only
Ipamorelin 200-300 mcg + CJC-1295 no-DAC 100 mcg per dose, pre-bed, 5-on/2-off (no-DAC daily; DAC weekly 1-2 mg)
Titration
1150200 mcg↑ dose · → time (≈4-week steps)
Reconstitution — illustrative, not a recommendation
Pre-blend 20 mg (10+10) + 3 mL BAC = 3.33 mg/mL each; 200 mcg each = 6 U on U-100. Confirm DAC vs no-DAC (changes frequency ~7x).
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. FDA flagged immunogenicity/anaphylaxis risk. Health Canada advisory Apr 2026.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 (Sept 2024 + 2026 wave)
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Phase I PK/PD per component only; the combo & long-term outcomes are animal/anecdotal. Both are abandoned pharma assets (ipamorelin failed Phase II ileus; CJC-1295/DAC halted after a trial death). Zero outcome RCTs for the combo.

04Safety
Contraindications
  • Active/recent cancer (GH/IGF-1 pro-proliferative)
  • Pituitary/hypothalamic diseasehard stop
  • Pregnancyhard stop
  • Uncontrolled diabetes
  • Active proliferative diabetic retinopathy
Key interactions
  • Insulin/antidiabetics (GH lowers insulin sensitivity)
  • Corticosteroids & somatostatin/octreotide (blunt GH response)
Serious signals
  • FDA immunogenicity/anaphylaxis warning
  • Ipamorelin IV death risk
  • CJC-1295 vasodilation/HR rise
Monitoring
IGF-1 (titrate within age/sex range), fasting glucose/HbA1c.
05Related in GH secretagogue
Tesamorelin
FDA-approved RCTs
grade A →
Sermorelin
human trials
grade B →
06Sources
1JCEM Teichman 2006
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high
← All peptides
GH secretagogue

CJC-1295 / Ipamorelin

mod-GRF(1-29) · NNC 26-0161

Most-searched peptide COMBINATION; the default GH-optimization stack in clinics and biohacking.

Evidence
B
human trials
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous
Community / anecdotal
Demand
#7
most-searched
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

Ipamorelin 200-300 mcg + CJC-1295 no-DAC 100 mcg per dose, pre-bed, 5-on/2-off (no-DAC daily; DAC weekly 1-2 mg)

Worked reconstitution example

Pre-blend 20 mg (10+10) + 3 mL BAC = 3.33 mg/mL each; 200 mcg each = 6 U on U-100. Confirm DAC vs no-DAC (changes frequency ~7x).

Titration
0501001502001wk 1150wk 5200 mcgwk 9dose (mcg) ↑time → (≈4-week steps)
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. FDA flagged immunogenicity/anaphylaxis risk. Health Canada advisory Apr 2026.
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 (Sept 2024 + 2026 wave)
PCAC review2026-07-23/24
WADAProhibited (S0)
03

Evidence — the honest read

Bhuman trials

Phase I PK/PD per component only; the combo & long-term outcomes are animal/anecdotal. Both are abandoned pharma assets (ipamorelin failed Phase II ileus; CJC-1295/DAC halted after a trial death). Zero outcome RCTs for the combo.

04

Safety

Contraindications
  • Active/recent cancer (GH/IGF-1 pro-proliferative)
  • Pituitary/hypothalamic diseasehard stop
  • Pregnancyhard stop
  • Uncontrolled diabetes
  • Active proliferative diabetic retinopathy
Key interactions
  • Insulin/antidiabetics (GH lowers insulin sensitivity)
  • Corticosteroids & somatostatin/octreotide (blunt GH response)
Serious signals
  • FDA immunogenicity/anaphylaxis warning
  • Ipamorelin IV death risk
  • CJC-1295 vasodilation/HR rise
Monitoring

IGF-1 (titrate within age/sex range), fasting glucose/HbA1c.

06

Sources

01JCEM Teichman 2006
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high